Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$2.15 - $3.64 $3,635 - $6,155
1,691 Added 137.93%
2,917 $6,000
Q3 2023

Oct 30, 2023

BUY
$2.15 - $3.64 $3,635 - $6,155
1,691 Added 137.93%
2,917 $6,000
Q2 2023

May 21, 2024

SELL
$3.17 - $5.82 $126 - $232
-40 Reduced 3.16%
1,226 $4,000
Q2 2023

Jul 27, 2023

SELL
$3.17 - $5.82 $126 - $232
-40 Reduced 3.16%
1,226 $4,000
Q1 2023

May 21, 2024

BUY
$3.94 - $7.05 $1,256 - $2,248
319 Added 33.69%
1,266 $4,000
Q1 2023

Apr 27, 2023

BUY
$3.94 - $7.05 $1,256 - $2,248
319 Added 33.69%
1,266 $5,000
Q4 2022

May 21, 2024

BUY
$4.7 - $9.98 $4,450 - $9,451
947 New
947 $4,000
Q4 2022

Jan 31, 2023

BUY
$4.7 - $9.98 $357 - $758
76 Added 8.73%
947 $5,000
Q3 2022

Oct 21, 2022

BUY
$4.13 - $8.79 $3,597 - $7,656
871 New
871 $7,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $51.2M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.